This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea.
Table of Contents
Slide 4: Dosage and Administration Slide 17: Cautions, Effects, and Interactions Slide 24: What to Tell Your Patient Slide 29: Reference
